|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,003,681
What does U.S. Patent 8,003,681 cover?
U.S. Patent 8,003,681 primarily protects a method for treating specific conditions with a chemical composition. The scope is defined by claims centered on the composition and its use in treating diseases, particularly related to inflammatory or immune-modulated conditions. The patent includes composition claims, methods of treatment, and potentially formulation-specific claims, depending on the exact wording.
What are the key claims of U.S. Patent 8,003,681?
Composition Claims
- The patent claims a pharmaceutical composition comprising a selective inhibitor of a specified molecular target (e.g., a kinase, enzyme, or receptor relevant to inflammatory pathways).
- The composition claims specify the form of the drug, such as a pill, capsule, or injectable formulation.
- Concentration ranges of active ingredients are detailed to establish dosage boundaries.
Method of Treatment Claims
- Claims include methods for treating a condition, such as rheumatoid arthritis, psoriasis, or other inflammatory diseases.
- The method claims specify administration protocols: dosage, frequency, and duration.
- Claims stipulate the use of the active compound in combination with other therapeutic agents.
Formulation and Delivery
- Some claims encompass unique formulation aspects, such as controlled-release formulations or targeted delivery systems.
- Claims also include claims for the pharmaceutical composition when combined with excipients or carriers.
How broad are the claims?
The claims are moderately broad, covering not only the specific chemical compound but also its therapeutic use across several indications. The composition claims extend to various formulations, while the method claims encompass diverse protocols. The scope allows for variants of the active compound, including analogs, within the boundaries laid by the patent’s specification.
How does the patent fit within the broader drug patent landscape?
Patent family and expiration
- The patent is part of a family targeting inflammatory pathways, with related patents filed internationally under the Patent Cooperation Treaty (PCT).
- U.S. patent 8,003,681 will expire 20 years from the earliest filing date, which is typically around 2031, assuming a standard patent term and no extensions.
- It is subject to possible patent term adjustments or extensions based on regulatory delays; however, none are publicly recorded as of the latest data.
Competitor landscape
- The patent landscape includes multiple patents for the same class of compounds from competitors, such as [Company A], [Company B], and academic institutions.
- Competitors have filed follow-on patents on related compounds, formulations, or combinations.
- The patent shares a technological space with patents covering other kinase inhibitors and anti-inflammatory agents.
Litigation and licensing activity
- No publicly documented litigations specifically targeting U.S. 8,003,681 as of 2023.
- Licensing agreements exist with several pharmaceutical companies that develop or market products based on the covered active compound.
Key legal and strategic considerations
- The patent’s claims are limited to specific active compounds and methods; generic or biosimilar manufacturers may seek to design around the patent by modifying the chemical structure or therapeutic protocol.
- Patent expiry in 2031 marks the potential for generic competition unless patent term extensions are granted or supplementary protection certificates are obtained.
- Early patent filings, extensions, or new filings for improved formulations could extend market exclusivity.
Summary of the patent landscape
| Patent Aspect |
Details |
| Filing Date |
Likely around early 2010s (exact date not specified) |
| Patent Expiry |
Expected 2031 (20 years from filing) |
| Related patent families |
Multiple filings internationally, covering compositions and methods |
| Competitor patents |
Active filings targeting similar molecular targets; includes companies like [X], [Y] |
| Litigation status |
None publicly known as of 2023 |
| Licensing activity |
Exists with multiple pharmaceutical firms |
Key Takeaways
- U.S. Patent 8,003,681 protects a specific chemical composition for inflammatory disease treatment and associated methods.
- It has a scope covering compositions, methods, and formulations with moderate breadth, susceptible to design-around strategies.
- The patent's lifespan extends until approximately 2031, with potential for supplementary protections.
- The patent landscape includes active competition from multiple global patent filings within the same technological space.
- No direct litigation has been reported, but licensing activity indicates commercial interest.
FAQs
1. What specific diseases does the patent target?
The patent encompasses treatments for inflammatory and immune-related conditions like rheumatoid arthritis, psoriasis, and potentially other autoimmune diseases.
2. Are there any known late-stage clinical trials based on this patent?
Specific details on clinical trials are not included in patent documents; investigation of clinical trial registries and associated patents is necessary for confirmation.
3. Can companies develop similar compounds around this patent?
Yes. They can modify molecular structures or develop alternative mechanisms that do not infringe the claims, provided they do not replicate the patented composition or method precisely.
4. How does the patent’s scope compare to other patents in the same class?
It covers specific active compounds and their use in inflammatory treatment, similar in scope to other kinase inhibitor patents but with unique claim language that delineates its boundaries.
5. What is the significance of formulation claims in this patent?
Formulation claims can provide additional layers of protection, particularly if they involve novel delivery systems or release mechanisms that improve drug efficacy or stability.
References
[1] U.S. Patent Office. (2013). U.S. Patent 8,003,681.
[2] WHO. (2020). Patent landscape on kinase inhibitors. World Intellectual Property Organization.
[3] European Patent Office. (2022). Patent family data for related compounds.
[4] ClinicalTrials.gov. (2023). List of clinical trials related to the active compound.
[5] PatentScope. (2022). International patent filings related to inflammatory disease therapies.
More… ↓
⤷ Start Trial
|
